Abstract
Recombinant plasmids have been obtained that lead to the accumulation of five- to ten-fold more puromycin-N-acetyl-transferase (PAC) mRNA and two- to three-fold more PAC activity than the already described plasmid pSV2pac [Vara et al., Nucl. Acids Res. 14 (1986) 4117-4124]. When these optimized recombinants were used for stable transformation to puromycin resistance, efficiencies up to 1 x 10(-2) were obtained, indicating that these pac-containing recombinants may be very useful dominant selectable markers for gene transfer in mammalian cells.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetyltransferases / biosynthesis
-
Acetyltransferases / genetics*
-
Animals
-
Cell Line
-
Cricetinae
-
Drug Resistance
-
Fibroblasts / drug effects
-
Fibroblasts / metabolism
-
Genetic Vectors*
-
Kidney
-
L Cells / drug effects
-
L Cells / metabolism
-
Mesocricetus
-
Mice
-
Plasmids
-
Puromycin / pharmacology
-
Recombinant Fusion Proteins / biosynthesis
-
Recombinant Fusion Proteins / genetics
-
Transformation, Genetic*
-
Vero Cells / drug effects
-
Vero Cells / metabolism
Substances
-
Recombinant Fusion Proteins
-
Puromycin
-
Acetyltransferases
-
puromycin N-acetyltransferase